Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Paul Brunetta"'
Publikováno v:
JMIR mHealth and uHealth, Vol 12, p e55239 (2024)
BackgroundDespite the growing availability of smoking cessation apps, low engagement and cessation rates have remained a significant challenge. To address this issue, we used a user-centered design to iteratively develop a mobile app (MO) to provide
Externí odkaz:
https://doaj.org/article/c0c076bab5d340999e4830864af11748
Autor:
Alvise Berti, Sophie Hillion, Amber M. Hummel, Young Min Son, Nedra Chriti, Tobias Peikert, Eva M. Carmona, Wayel H. Abdulahad, Peter Heeringa, Kristina M. Harris, E. William St. Clair, Paul Brunetta, Fernando C. Fervenza, Carol A. Langford, Cees G.M. Kallenberg, Peter A. Merkel, Paul A. Monach, Philip Seo, Robert F. Spiera, John H. Stone, Guido Grandi, Jie Sun, Jacques-Olivier Pers, Ulrich Specks, Divi Cornec, for the RAVE-ITN Research Group
Publikováno v:
JCI Insight, Vol 6, Iss 22 (2021)
BACKGROUND Little is known about the autoreactive B cells in antineutrophil cytoplasmic antibody–associated (ANCA-associated) vasculitis (AAV). We aimed to investigate tolerance checkpoints of circulating antigen-specific proteinase 3–reactive (P
Externí odkaz:
https://doaj.org/article/17108e393aed484eae0eb4f26d7643a8
Autor:
Kasia Owczarczyk, Matthew D. Cascino, Cecile Holweg, Gaik W. Tew, Ward Ortmann, Timothy Behrens, Thomas Schindler, Carol A. Langford, E. William St. Clair, Peter A. Merkel, Robert Spiera, Philip Seo, Cees G.M. Kallenberg, Ulrich Specks, Noha Lim, John Stone, Paul Brunetta, Marco Prunotto, the RAVE-ITN Research Group
Publikováno v:
JCI Insight, Vol 5, Iss 18 (2020)
BACKGROUND Baseline expression of FCRL5, a marker of naive and memory B cells, was shown to predict response to rituximab (RTX) in rheumatoid arthritis. This study investigated baseline expression of FCRL5 as a potential biomarker of clinical respons
Externí odkaz:
https://doaj.org/article/b7bd1818f0e642e5849a9f696ba49b07
Autor:
Hans-Joachim Anders, Brad Rovin, David Jayne, Paul Brunetta, Rosanna Coppo, Anne Davidson, Satish Kumar Devarapu, Dick de Zeeuw, Jeremy Duffield, Dirk Eulberg, Alberto Fierro, Jürgen Floege, Steffen Frese, Loïc Guillevin, Stephen Holdsworth, Jeremy Hughes, Ralph Kettritz, Malte Kluger, Christian Krebs, Larissa Lapteva, Adeera Levin, Jinhua Li, Liz Lightstone, Matthias Mack, Ladan Mansouri, Stephen McAdoo, Eoin McKinney, Ulf Panzer, Samir Parikh, Charles Pusey, Chaim Putterman, Ton Rabelink, Andreas Radbruch, Andrew Rees, Mary Reilly, Marlies Reinders, Giuseppe Remuzzi, Piero Ruggenenti, Steven Sacks, Thomas J Schall, Catherine Meyer-Schwesinger, Kumar Sharma, Yusuke Suzuki, Nicola M. Tomas, Ming-Hui Zhao
Publikováno v:
Kidney International Reports, Vol 1, Iss 4, Pp 327-339 (2016)
To date, the treatment of immune-mediated kidney diseases has only marginally benefited from highly specific biological drugs that have demonstrated remarkable effects in many other diseases. What accounts for this disparity? In April 2016, the Inter
Externí odkaz:
https://doaj.org/article/31c0023f19ae480299b2c0347a697892
Autor:
Alvise Berti, Sophie Hillion, Maximilian F. Konig, Marta Casal Moura, Amber M. Hummel, Eva Carmona, Tobias Peikert, Fernando C. Fervenza, Cees G.M. Kallenberg, Carol A. Langford, Peter A. Merkel, Paul A. Monach, Philip Seo, Robert F. Spiera, Paul Brunetta, E. William St. Clair, Kristina M. Harris, John H. Stone, Guido Grandi, Jacques‐Olivier Pers, Ulrich Specks, Divi Cornec
Publikováno v:
Arthritis & Rheumatology. 75:736-747
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b09bd7ca4c69ee82613e54f0fdec890b
https://doi.org/10.1002/art.42388
https://doi.org/10.1002/art.42388
Autor:
J Garg, Analia Alvarez, Elizabeth Zuta-Santillan, Paul Brunetta, Ana Malvar, Cary M. Looney, Brad H. Rovin, Thomas Schindler, Richard Furie, Matthew D Cascino, Imran Hassan, Gustavo Aroca, Hilda Fragoso-Loyo
Publikováno v:
Annals of the Rheumatic Diseases
ObjectiveRandomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II anti-CD20 monoclonal antibody that induces potent B-cell d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbd8426231641fd20e5ab9bdd41bcf93
https://doi.org/10.1136/annrheumdis-2021-220920
https://doi.org/10.1136/annrheumdis-2021-220920
Autor:
Alvise, Berti, Sophie, Hillion, Maximilian F, Konig, Marta, Casal Moura, Amber M, Hummel, Eva, Carmona, Tobias, Peikert, Fernando C, Fervenza, Cees G M, Kallenberg, Carol A, Langford, Peter A, Merkel, Paul A, Monach, Philip, Seo, Robert F, Spiera, Paul, Brunetta, E William, St Clair, Kristina M, Harris, John H, Stone, Guido, Grandi, Jacques-Olivier, Pers, Ulrich, Specks, Divi, Cornec
Publikováno v:
Arthritisrheumatology (Hoboken, N.J.).
Autoreactive B cells are responsible for ANCA production in ANCA-associated vasculitis (AAV). Rituximab depletes circulating B cells including autoreactive ones. We aimed to evaluate changes and associations with relapse of the circulating autoreacti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::813b3edd4452c6b8c59889c8e2796c9d
https://pubmed.ncbi.nlm.nih.gov/36281741
https://pubmed.ncbi.nlm.nih.gov/36281741
Autor:
Carol A. Langford, Paul A. Monach, Kristina M. Harris, Alvise Berti, Paul Brunetta, Robert Spiera, Jacques-Olivier Pers, Divi Cornec, E. William St. Clair, Peter Heeringa, Ulrich Specks, Philip Seo, Tobias Peikert, Sophie Hillion, Amber M. Hummel, Peter A. Merkel, Young Min Son, Nedra Chriti, Wayel H. Abdulahad, Fernando C. Fervenza, Jie Sun, Cees G. M. Kallenberg, John H. Stone, Eva M. Carmona, Guido Grandi
Publikováno v:
JCI Insight, 6(22):150999. AMER SOC CLINICAL INVESTIGATION INC
JCI Insight
JCI Insight
BACKGROUND Little is known about the autoreactive B cells in antineutrophil cytoplasmic antibody–associated (ANCA-associated) vasculitis (AAV). We aimed to investigate tolerance checkpoints of circulating antigen-specific proteinase 3–reactive (P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ac6ce95d3a976110d1a0de400e51e18
https://research.rug.nl/en/publications/34b3ff7d-2935-40e5-96d1-3740358d1b9f
https://research.rug.nl/en/publications/34b3ff7d-2935-40e5-96d1-3740358d1b9f
Autor:
Jae Il Shin, Andreas Kronbichler, Carol A. Langford, Paul A. Monach, E. William St. Clair, Philip Seo, John H. Stone, Cees G. M. Kallenberg, Duvuru Geetha, Gert Mayer, Gary S. Hoffman, Fernando C. Fervenza, Robert Spiera, Peter A. Merkel, Ulrich Specks, Karina A. Keogh, Steven R. Ytterberg, Johannes Leierer, Paul Brunetta
Publikováno v:
Arthritis & Rheumatology, 71(11), 1888-1893. Wiley
Arthritis & Rheumatology (Hoboken, N.j.)
Arthritis & Rheumatology (Hoboken, N.j.)
Objective To assess the frequency of venous thromboembolism (VTE) events in the Rituximab in Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (RAVE) trial and identify novel potential risk factors. Methods VTE events in 197 patients e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::793bc7dc497c69e38385b34d26e2fdba
https://doi.org/10.1002/art.41017
https://doi.org/10.1002/art.41017
Publikováno v:
Successful Drug Discovery
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::93011b1215456fdc61fb99f666c1fe32
https://doi.org/10.1002/9783527814695.ch7
https://doi.org/10.1002/9783527814695.ch7